*ST Medication announced that its wholly-owned subsidiary Huangshan Tianmu Pharmaceutical Co., Ltd. plans to invest 10,000 million yuan to increase production capacity and technological transformation. The estimated construction period of the project is 30 months. The project aims to optimize the production capacity structure, build intelligent, digital and information chemical plants, and enhance market competitiveness. The investment has been reviewed and approved by the board of directors and still needs to be submitted to the shareholders' meeting for consideration.
*ST目药：全资子公司黄山市天目药业有限公司拟投资10,000万元实施产能提升及技术改造项目
*ST Eye Medicine: Huangshan Tianmu Pharmaceutical Co., Ltd., a wholly-owned subsidiary, plans to invest RMB 10,000 million to implement capacity improvement and technological transformation projects
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.